Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
BeOne Medicines
Eli Lilly and Company
Terremoto Biosciences Inc.
Incyte Corporation
Blueprint Medicines Corporation
Avenzo Therapeutics, Inc.
Incyclix Bio
Pfizer
Syros Pharmaceuticals
AstraZeneca